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Overexposure of microorganisms to conventional drugs has led to resistant species that 
require new treatment strategies. This study aimed to prepare and characterize a 
nanocarrier of miconazole (MCZ) based on iron oxide nanoparticles (IONPs) 
functionalized with chitosan (CS), as well as to test its antifungal activity against 
biofilms of Candida albicans and Candida glabrata. IONPs-CS-MCZ nanocarrier was 
prepared by loading MCZ on CS-covered IONPs and characterized by physicochemical 
methods. Minimum inhibitory concentration (MIC) of the nanocarrier was determined 
by the microdilution method. Biofilms were developed (48 h) in microtiter plates and 
treated with MCZ-carrying nanocarrier at 31.2 and 78 µg/mL, in both the presence and 
absence of an external magnetic field (EMF). Biofilms were evaluated by total biomass, 
metabolic activity, cultivable cells (CFU), extracellular matrix components, scanning 
electron microscopy and confocal microscopy. Data were analyzed by two-way 
ANOVA and Holm-Sidak test (p<0.05). A nanocarrier with diameter lower than 50 nm 
was obtained, presenting MIC values lower than those found for MCZ, and showing 
synergism for C. albicans and indifference for C. glabrata. IONPs-CS-MCZ did not 
affect total biomass and extracellular matrix. IONPs-CS-MCZ containing 78 µg/mL 
MCZ showed a superior antibiofilm effect to MCZ in reducing CFU and metabolism for 
single biofilms of C. albicans and dual-species biofilms. The EMF did not improve the 
nanocarrier effects. Microscopy confirmed the antibiofilm effect of the nanocarrier. 
IONPs-CS-MCZ was more effective than MCZ mainly against C. albicans planktonic 
cells and number of CFU and metabolism of the biofilms. 
 







Candida species are opportunistic yeasts that usually colonize oral cavity, 
vagina, and respiratory and intestinal tracts of humans [1, 2]. In fact, around 23 to 49% 
of women over 50 years-old are likely to present vulvovaginal candidiasis [3], while the 
mortality rate of hospitalized patients with invasive candidiasis ranges from 14 to 80% 
[4-6]. Moreover, the Candida genus is present in the oral microbiome of 25 to 75% of 
healthy people [7-9]. However, clinical imbalances caused by immunologic shifts, use 
of dentures, antibiotics and corticosteroids, as well as diabetes, HIV syndrome and other 
factors can lead to oral candidiasis [7, 10-12]. This clinical condition is characterized by 
erythematous, pseudomembranous and hyperplastic lesions, and Candida-related 
lesions may also be present, such as angular cheilitis, rhomboid glossitis and denture 
stomatitis (DS) [7]. Candida albicans followed by Candida glabrata are frequently 
detected in cases of oral candidiasis, and are the most prevalent species in DS, an oral 
disease that affects from 15 to 70% of complete denture wearers [13-15].  
Miconazole (MCZ) is an imidazole with topical indication for candidiasis, acting 
against fungi and a large set of bacteria [16, 17]. Noteworthy, MCZ has shown an 
antimicrobial effect on fluconazole-resistant Candida species [18, 19]. However, MCZ 
can interact with other drugs, reducing its antimicrobial efficacy, and for some 
presenting local irritation for some patients [5]. Notably, within biofilms C. albicans 
sessile cells may exhibit tolerance (1 to 10%), even when exposed to high 
concentrations of MCZ [20]. Moreoevr, azole cross resistance of C. albicans and C. 
glabrata to this antifungal has been reported [21, 22].  
The biomedical field has greatly benefited from nanotechnology, as detailed in a 
comprehensive literature review, with applications for enhancing both the diagnosis and 
treatment of several diseases [23]. In fact, different pathways (e.g., economic and 
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ecological routes) have been used for the synthesis of copper, selenium, magnesium 
oxide and zinc oxide nanoparticles [24-27], which have shown interesting antioxidant 
and antimicrobial properties. 
Among the nanotechnology-based therapies available, drug delivery systems 
have been developed to increase drug effectiveness and reduce therapeutic 
concentrations compared to conventional treatments [28]. Recently, nystatin-conjugated 
bismuth oxide nanoparticles were shown to promote expressive reductions in biofilm 
formation by C. albicans (94.2%) and Escherichia coli (84.9%) [29]. Iron oxide 
magnetic nanoparticles (IONPs) have also been used in different biomedical 
applications, including drug hyperthermia, magnetic resonance and design of drug 
delivery systems [30]. Although there are few studies on the antibiofilm activity of 
IONPs, a recent study showed that the magnetic properties of these nanoparticles may 
be exploited by using an external magnetic field to conduct IONPs within the biofilm. 
Here it was reported that by creating artificial channels they have the possibility of 
enhance drug penetration and thereby increasing the cell death [31].  
IONPs surface may be coated with different organic and inorganic compounds 
(i.e. surfactants, polymers, gold, silica, peptides and others), which makes these 
nanoparticles more biocompatible and prevents their aggregation and oxidation [32]. In 
this sense, natural polymers such as chitosan (CS) have been used as a nanoparticle 
coating, ought to the biocompatibility, mucoadhesive, hemostatic and antimicrobial 
properties of this polymer [32-35]. IONPs-based nanocarriers functionalized with CS 
proved to be effective against C. albicans and different bacteria [36], and successfully 
favored the efficacy of broad spectrum drugs such as chlorhexidine and fluconazole 
against oral pathogenic microorganisms in vitro [33, 37]. No other work, however, has 
investigated the use of CS-coated IONPs as a therapeutic tool to improve the antifungal 
effect of MCZ in order to overcome the above-mentioned limitations of this drug. 
5 
 
Therefore, the aim of this study was to prepare and characterize a MCZ nanocarrier 
based on CS-coated IONPs, as well as to test its antifungal activity against single- and 
dual-species biofilms of C. albicans and C. glabrata in vitro, both in the presence and 
absence of an external magnetic field. The null hypothesis of the study was that the 
antifungal effect of the IONP-CS-MCZ nanocarrier would not differ from that observed 
for MCZ alone, regardless of the presence of an external magnetic field during the 
treatment period. 
 
2. Materials and methods 
 
2.1. Preparation and characterization of the IONPs-CS-MCZ nanocarrier  
Colloidal IONPs (Fe3O4) were supplied by nChemi Engenharia de Materiais 
(São Carlos, São Paulo, Brazil), while CS and MCZ were purchased from Sigma-
Aldrich (St. Louis, MO, USA). The preparation and characterization of the IONPs-CS-
MCZ nanocarrier were conducted as described elsewhere [33]. In brief, CS was 
solubilized in 2% acetic acid under constant stirring during 24 h at room temperature. 
CS-coated IONPs were obtained by mixing equal volumes of IONPs and CS, both at 
1400 µg/mL of these components. In order to obtain the IONP-CS-MCZ nanocarrier, 
500 µg MCZ were added to the IONP-CS compound (700 µg/mL), followed by a 1-h 
solubilization process under constant magnetic stirring at room temperature. Next, the 
nanocarrier was characterized by transmission electron microscopy (TEM), dynamic 
light scattering (DLS), X-ray powder diffraction (XRD), Fourier-transform infrared 
spectroscopy (FTIR) and thermogravimetric analysis (TGA) 
 
2.2. Strains and growth conditions 
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The present study used two reference strains from American Type Culture 
Collection (ATCC): C. albicans ATCC 10231 and C. glabrata ATCC 90030. Stock 
cultures (-80°C) of both strains were aerobically cultivated on Sabouraud Dextrose Agar 
(SDA; Difco, Le Pont de Claix, France) plates at 37°C. After 24 h, colonies of both 
stains from SDA plates were separately inoculated overnight in Sabouraud Dextrose 
Broth (SDB; Difco) at 37°C. To adjust the inoculum concentration, the fungal cells 
were harvested by centrifugation (8000 rpm, 5 min) and washed twice in phosphate 
buffered saline (PBS; pH 7, 0.1 mol/l). Artificial saliva (AS; pH 6.8) [38] was the 
medium used to resuspend the cells at 1 × 107 cells/mL or 2 × 107 cells/mL, 
respectively, for single- and dual-species biofilms. 
 
2.3. Determination of the minimum inhibitory concentration (MIC) on planktonic cells  
The broth microdilution method was employed to determine the MIC of the 
IONPs-CS-MCZ nanocarrier against the studied strains, as previously described [39]. 
Briefly, cell suspensions of C. albicans and C. glabrata were adjusted in saline solution 
to a concentration corresponding to the standard 0.5 of McFarland scale (0.5 to 2.5 × 
103 cells/mL) and then diluted in saline solution (1:5). Subsequently, this was diluted in 
Roswell Park Memorial Institute (RPMI 1640; Sigma-Aldrich) medium (1:20). Next, 
100 µL of each yeast suspension were added to the wells of a 96-well flat bottom plate 
(Costar, Tewksbury, USA) containing 100 µL of each specific concentration of the 
nanocarrier (0.09-50 µg/mL) previously diluted in RPMI 1640. IONPs (0.13-70 
µg/mL), CS (0.13-70 µg/mL) and MCZ (0.09-50 µg/mL) alone were tested as controls. 
After incubation for 48 h at 37°C, the MIC values were visually established as the 
lowest concentrations capable of completely (100%) inhibiting the yeasts’ growth. In 
order to evaluate the type of interaction among the nanocarrier’s compounds, the 
fractional inhibitory concentration (FIC) indexes were calculated, based on the MIC 
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results, as detailed elsewhere [40]. MIC assays were repeated in triplicate on three 
independent occasions.  
 
2.4. Biofilm formation and treatment 
For single-species biofilm formation, 200 µL of each yeast suspension (1 × 107 
cells/mL in AS) were added into wells of 96-well flat bottom plates, whereas for dual-
species biofilms 100 µL of each microbial suspension  (2 × 107 cells/mL for C. albicans 
+ 2 × 107 cells/mL for C. glabrata – [both final conc. of 1 x 10 cells/mL]) were 
incorporated into each well. The microtiter plates were then aerobically incubated at 
37°C. After 48-h biofilm formation (with refreshment of the AS medium after the first 
24 h), single- and dual-species biofilms were treated during 24 h with the MCZ-
containing nanocarrier at two different concentrations: 31.2 (IONPs-CS-MCZ31.2) and 
78 µg/mL (IONPs-CS-MCZ78). These concentrations corresponded to 20- and 50-fold 
the nanocarrier MIC for C. glabrata (1.56 µg/mL). All biofilm assays had appropriate 
controls, including 110 µg/mL IONPs, 110 µg/mL CS, 78 µg/mL MCZ and untreated 
biofilms as negative control (NC). Biofilm treatment was performed both in the 
presence and absence of an external magnetic field. For the set of experiments involving 
magnetic field, magnetic plates (Supergauss Prod. Magnéticos Ltda., São Paulo, Brazil) 
of 10 × 100 × 150 mm with magnetic flux density between 3900~4000 G were 
positioned under the 96 well-plates during the 24-h treatment period.  
 
2.5. Biofilm quantification  
Following treatment, all biofilms were rinsed once with PBS to remove non-
adhered cells, and a crystal violet (CV) staining and XTT reduction assay were 
employed, respectively, to quantify the total biofilm biomass and metabolic activity of 
biofilm cells, as previously described [41]. For quantification of colony-forming units 
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(CFUs) the treated biofilms were scraped from the bottom of the plates, suspended in 
PBS (1 ml) and homogenized in vortex (90 s). Serial dilutions were then performed in 
PBS were plated on SDA for single biofilms, and on CHROMagar Candida (Difco) for 
dual-species biofilms. The agar plates were incubated at 37°C, and the CFUs counted 
after 24 to 48h [40]. The results of total biomass, metabolic activity and number of 
CFUs were expressed as a function of the well area (Abs/cm2 and log10 CFU/cm2). 
The compositional analysis of the biofilms’ extracellular matrix was also 
performed. Briefly, single- and dual-species biofilms were developed in 24-well plates 
containing 1 mL of cell suspension, and treated with the nanocarrier and controls, as 
detailed above. For matrix extraction, the resulting biofilms were scraped from the 
wells, resuspended in PBS, sonicated on ice (30 s; 30 w) and vortexed for 2 min. 
Afterwards, biofilm suspensions were centrifuged at 3000 g for 10 min and the 
supernatant, filtered through a nitrocellulose filter (0.22 µm) [42, 43]. The protein 
content of the extracellular matrix was determined by the bicinchoninic acid method 
(BCA kit; Sigma-Aldrich), using bovine serum albumin as standard [44]. Total 
carbohydrate content was estimated using glucose as standard [42, 43, 45]. To assess 
the content of DNA from matrix biofilm, 1.5 µL of the supernatant was pipetted into a 
NanoDrop device (Eon Microplate Spectrophotometer; Bio Tek, Winooski, USA) and 
spectrophotometrically analysed  at 260 nm and 280 nm [46]. Total contents of protein, 
carbohydrate and DNA were expressed as a function of the liquid phase of the 
extracellular matrix (mg/mL). 
 
2.6. Structural analysis of biofilms 
Scanning electron microscopy (SEM) and confocal laser scanning microscopy 
(CLSM) were employed to visualize the ultrastructure of dual-species Candida biofilms 
treated with IONPs-CS-MCZ nanocarrier and controls. For this, biofilms were formed 
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at the bottom of 24-well plates for SEM, and on sterile coverslips into 24-well plates for 
CLSM. Biofilm treatment was performed in the absence of an external magnetic field, 
as described above. For SEM preparation, the samples were serially washed in ethanol 
for dehydration (70% for 10 min, 95% for 10 min and 100% for 20 min), air-dried in a 
desiccator, and cut from the bottom of the plates. Samples were then positioned onto 
aluminum stubs before being coated with gold, and qualitatively analyzed by SEM 
(FEG-VP Supra 35; Carl Zeiss, Jena, Thüringen, Germany)[39]. As for CLSM analysis, 
the resulting biofilms were stained with 200 µL of a solution containing 3µg/mL 
SYTO9 green fluorescent dye and 3µg/mL propidium iodide for 20 to 30 min at room 
temperature, protected from light [42]. Biofilm samples were then gently rinsed with 
sterile water and analyzed under a confocal microscope (Nikon C2/C2si, Tokyo, Japan) 
at 488/500-570 nm for SYTO9 dye and 561/570-1000 nm for propidium iodide. 
Fluorescent green and red colors represent living and dead cells, respectively. 
 
2.7. Statistical analysis  
All biofilm assays were conducted in triplicate on three separate occasions. Data 
presented normal (Shapiro-Wilk test) and homogeneous (Cochrane test) distribution, 
except for DNA (C. glabrata and dual-species biofilms) and protein (C. albicans and 
dual-species biofilms). Results were submitted to 2-way ANOVA, considering the 
different compounds and the presence of an external magnetic field as variation factors. 
A Holm-Sidak test was applied for multiple-comparisons when applicable. SigmaPlot 
software (version 12.0; Systat Software Inc., San Jose, USA) was used, adopting p < 






3.1. Characterization of the IONPs-CS-MCZ nanocarrier 
The characterization results of IONPs alone and CS-coated IONPs were 
previously described by our group [33]. Therefore, this section only presents the 
characterization of the IONPs-CS-MCZ nanocarrier. TEM and DLS analyzes were used 
to estimate the morphology and average size of the nanocarrier. By TEM it was possible 
to observe a predominantly spherical shape for IONPs and MCZ particles, with a 
diameter lower than 50 nm for the IONPs-CS-MCZ nanocarrier (Fig. 1a). It was also 
possible to note the MCZ particles adhered to the CS-coated IONPs, thus forming the 
nanocarrier (Fig. 1a). In turn, DLS analysis showed that the average hydrodynamic size 
of the nanocarrier was close to 180 nm (Fig. 1b). Regarding the nanocarrier’s crystalline 
structure, the XRD pattern obtained was similar to that seen for IONPs alone, and 
revealed a spinel-type structure [33]. 
FTIR analysis revealed the chemical constitution of the IONPs-CS-MCZ 
nanocarrier. Characteristic bands of IONPs [33] and CS [33] were seen in the 
nanocarrier’s FTIR spectrum (Fig. 1c). Absorption peaks around 1585 cm-1, 1473 cm-1 
(C-C of two dichlorobenzene), 1385 cm-1 (C-C and C-H of imidazole) and 1327 cm-1 
(C-H of two dichlorobenzene), which are indicative of MCZ [47], were also detected 
(Fig. 1c). For TGA, a marked mass loss was seen from 200°C, suggesting CS 
degradation and MCZ melting (Fig. 1d). Analyzing the temperature range from 400 to 
800°C, the thermogravimetric curve for IONPs-CS-MCZ (Fig. 1d) showed a similar 
mass loss pattern to that previously found for IONPs e CS-coated IONPs[33], thus 
evidencing that all MCZ incorporated was successfully conjugated to the IONPs-CS 
compound. 
 
3.2. Determination of the MIC 
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The results of planktonic cell susceptibility testing are shown in Table 1. For C. 
albicans, the nanocarrier promoted an 8-fold reduction in the MCZ MIC value 
compared to the antifungal applied alone, while for C. glabrata this reduction was 2- to 
4-fold. Furthermore, C. albicans was slightly more susceptible to MCZ and the 
nanocarrier than C. glabrata, whereas IONPs and CS alone did not inhibit the growth of 
both strains at 140 µg/mL. The association of compounds forming the nanocarrier was 
then classified as synergistic and indifferent, respectively for C. albicans and C. 
glabrata. 
 
3.3. Biofilm quantification  
For single- and dual-species biofilms treated in the presence or absence of an 
external magnetic field, none of the compounds assessed were able to promote 
significant decreases in total biomass compared to NC groups (Fig. 2).  
For C. albicans and mixed biofilms, MCZ and IONPs-CS-MCZ78 were shown 
to be the only compounds that led to significant reductions compared to NCs, both in 
the presence and in absence of an external magnetic field (Fig. 3a and c). IONPs-CS-
MCZ78 significantly differed from all other groups and produced the highest reductions 
in biofilm metabolism compared to NCs (93.04-94.40%; Fig. 3a and c), regardless of 
the use of a magnetic field. For single biofilm of C. glabrata, MCZ, IONPs-CS-
MCZ31.2 and IONPs-CS-MCZ78 did not differ from each other and promoted 
significant reductions in the metabolic activity (ranging from 64.15 to 98.27%) 
compared to the NC (Fig. 3b). The use of an external magnetic field did not influence 
the metabolism results for all biofilms (Fig. 3). 
CFU enumeration results for single-species biofilms of C. albicans and C. 
glabrata showed that CS, MCZ and IONPs-CS-MCZ31.2 were able to significantly 
reduce the number of cultivable cells compared to NCs (Fig. 4a and b). However, 
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IONPs-CS-MCZ78 was the most effective treatment, differing significantly from all 
groups and promoting cell number decreases in comparison to the NCs ranging from 
1.21- to 1.42-log10 in both the presence and absence of an external magnetic field (Fig. 
4a and b). For C. albicans in dual-species biofilms, IONPS-CS-MCZ78 also exhibited 
the highest reductions compared to the NCs (1.85-2.05-log10; Fig. 4c). As for C. 
glabrata in dual-species biofilms, MCZ and IONPs-CS-MCZ78 were the most effective 
compounds in reducing the number of CFUs, without significant differences between 
them (Fig. 4d). The presence of an external magnetic field only influenced the CFU 
quantification of C. albicans in dual-species biofilms treated with IONPs (Fig. 4c). 
For all biofilms evaluated, treatments with IONPs-CS-MCZ and controls did not 
affect protein (Table 2), carbohydrate (Table 3, Supplementary Material) and DNA 
(Table 4, Supplementary Material) contents of the extracellular matrix. In addition, the 
use of an external magnetic field during biofilm treatment did not interfere with the 
results of matrix composition. 
 
3.4. Structural analysis of biofilms 
SEM images revealed that the untreated dual-species biofilm consisted of a 
dense and robust network of interconnected yeasts and hyphae, forming a multilayer 
structure (Fig. 5a). Biofilms treated with IONPs, CS and IONPs-CS-MCZ31.2 exhibited 
the same structural pattern observed for the NC group (Fig. 5b, c and e). On the other 
hand, MCZ and IONPs-CS-MCZ78 produced ruptures in the biofilms, generating less 
dense structures, with more visualization of polystyrene surface areas (Fig. 5d and f). 
Some particle agglomerates (CS and IONPs) were also observed in biofilms exposed to 
CS (Fig. 5c), IONPs-CS-MCZ31.2 (Fig. 5e) and IONPs-CS-MCZ78 (Fig. 5f). 
According to CLSM images, biofilms treated with CS, MCZ, IONPs-CS-MCZ31.2 and 
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IONPs-CS-MCZ78 showed higher number of non-viable cells compared to the NC 
group (Fig. 6). 
 
4. Discussion 
The constant exposure of pathogenic microorganisms to conventional drugs has 
led to improved mechanisms of resistance, making it difficult to treat diseases, thus 
creating a generation of resistant microorganisms, known as ‘superbugs’ [48]. Within 
this context, the present study investigated the potential of a nanocarrier based on CS-
coated IONPs to improve the antifungal efficacy of MCZ against pathogenic fungal 
biofilms. The study's null hypothesis was partially rejected, since the nanocarrier effects 
on planktonic cells and on some biofilm parameters (CFUs for all biofilms, and 
metabolic activity for single biofilms of C. albicans and dual-species biofilms) were 
superior to those found for MCZ alone. 
The results of characterization shown in Fig. 1 evidenced the successful 
assembly of IONPs-CS-MCZ as a functional nanocarrier. TEM results confirmed a 
diameter lower than 50 nm for the nanocarrier, which ensures that this conjugate can be 
explored as an alternative nanotherapy. In contrast, DLS results indicated a large 
hydrodynamic diameter (around 180 nm; Fig. 1b). DLS is an indirect method that 
calculates sample size by the frequency of movement of particles in aqueous medium 
[49]. Thus, this technique is very sensitive to aggregation and may generate different 
results from those obtained for imaging techniques of dried samples, as TEM [49]. Due 
to its biocompatibility, biodegradability and stability in acidic pH, CS is frequently used 
as a coating for IONPs as this polymer usually adsorbs to these nanoparticles through 
glycosidic bonds [50, 51]. In turn, MCZ probably bound to CS via electrostatic 
attraction between the amine groups of CS and the negative charge of MCZ [52]. Taken 
together, these physicochemical phenomena explain how the nanocarrier was formed.  
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As for MIC determination, IONPs-CS-MCZ was more effective than MCZ alone 
on C. albicans and C. glabrata planktonic cells (Table 1). For planktonic C. albicans, 
the nanocarrier effect was the result of a synergistic interaction among the compounds 
present in the nanocarrier, as shown by the FIC index. MCZ causes accumulation of 
reactive oxygen species (ROS) in the fungal cytoplasm, which can lead to a fungicidal 
effect. Moreover, a previous study showed that even before ROS led to cell death, the 
majority of C. albicans cells exposed to MCZ were already necrotic [20]. It was 
suggested that prior to ROS production, MCZ affects the fungal actin cytoskeleton and 
creates channels in the mitochondrial membrane [20]. Regarding the mechanisms of 
antimicrobial action of CS, it was hypothesized that its positive charge interacts with the 
negatively charged cell membrane phospholipids, leading to increase in the membrane 
permeability, leakage of cell contents and, consequently, cell death [53]. CS also 
operates against C. albicans antagonizing the SAGA complex, which coordinates Ada2 
and ABC transporter-encoding genes such as CDR1 and MDR1, and altering the 
integrity of cell surface [54]. In addition, IONPs-CS may increase ROS production [55]. 
All the above-mentioned context could explain the synergistic effect found for IONPs-
CS-MCZ on C. albicans in planktonic culture, since the nanocarrier combines drugs 
with different mechanisms of action. 
C. glabrata, on the other hand, was shown to be less susceptible to MCZ and 
nanocarrier, with MIC values 2- to 8-fold higher than those found for C. albicans (Table 
1). Exposure to MCZ may lead to mitochondrial injuries in C. glabrata that cause 
upregulation of efflux pumps genes (Cdr1, Cdr2, Snq2 and Qndr2) associated with 
azole resistance, even before ROS accumulation causes its effect, thus increasing 
resistance to MCZ for this fungal pathogen [56, 57]. Furthermore, although Ada2 
controls antifungal drug tolerance and cell wall integrity in C. glabrata, it has a 
different role from that observed in C. albicans and does not regulate ABC transporter-
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encoding genes such as CDR1, CDR2 (PDH1) or SNQ2 [58]. Thus, even if CS may 
attack Ada2 in C. glabrata, a different mechanism is involved, which could justify the 
indifference found for IONPs-CS-MCZ on C. glabrata planktonic cells.  
Regarding biofilm assays, promising results were found for metabolic activity 
and CFU counting, considering that the IONPs-CS-MCZ78 nanocarrier was more 
effective than 78 µg/mL MCZ in reducing these parameters (Figs 3 and 4). These results 
are in agreement with SEM observations, which demonstrated greater ruptures and 
ultrastructure alterations in dual-species biofilms promoted by IONPs-CS-MCZ78, 
compared to other groups (Fig. 5). All treatments also generated biofilms with visually 
higher presence of dead cells in comparison to NC and IONPs alone, as displayed by 
CLSM (Fig. 6). As CS and MCZ alone were able to promote significant reductions in 
CFU and metabolism for some biofilms, the results found for IONPs-CS-MCZ78 may 
reflect a combined action of the antimicrobial effects of CS and MCZ, as justified for 
MIC results. The antibiofilm activity of IONPs-CS-MCZ78 was also dependent on the 
presence of MCZ at 78 µg/mL, since a dose-dependent effect was noted in comparison 
to its counterpart containing 31.2 µg/mL MCZ (IONPs-CS-MCZ31.2). In fact, the 
simultaneous analysis of SEM and CLSM indicate that despite both nanocarriers 
(IONPs-CS-MCZ31.2 and IONPs-CS-MCZ78) led to higher proportions of non-viable 
cells compared with the NC group, only the nanocarrier at the highest concentration 
(IONPs-CS-MCZ78) promoted marked ruptures within the biofilms (Fig. 5 and 6).  On 
the other hand, nanocarrier and controls did not affect the total biofilm biomass (Fig. 2) 
and extracellular matrix components (Tables 2, 3 and 4). Therefore, all biofilm results 
analyzed together indicate that the IONPs-CS-MCZ78 nanocarrier was able to cross the 
extracellular matrix without changing it, exclusively by acting at cellular level (affecting 
cell viability and metabolism). Indeed, nanocarriers are built for the purpose of 
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circumventing the physical barriers and penetrating at the most profound layers of the 
biofilm, due to its size advantages [32].  
Magnetic nanoparticles may be additionally guided by external magnetic forces 
to the cell target [59]. Inside biofilms, magnetic fields may create artificial channels and 
increase drug penetration, improving the antimicrobial effect [31, 60]. In this sense, the 
current study tested whether the presence of a static one-side magnetic field (positioned 
at the bottom of 96-well plates) would add any benefit to the nanocarrier's antibiofilm 
effect. However, in general the quantitative results showed no differences between 
biofilms treated in both the presence and absence of an external magnetic field. It is 
highly likely that the prolonged time of treatment used (24 h) might have been sufficient 
for nanocarrier penetration into the deeper layers of biofilms treated in the absence of 
magnetic field, so that any possible effect occurring within the initial exposure time 
could not be observed. Furthermore, this study did not use a switched magnetic field, 
which could create additional channels and improve drug efficacy [61]. 
Another interesting result was the higher effectiveness of the IONPs-CS-MCZ78 
nanocarrier compared to MCZ alone, mainly for C. albicans in single- and dual-species 
biofilms (Figs 3 and 4). From a clinical perspective, these findings highlight the 
potential of the MCZ nanocarrier as a topical treatment to fight recurrent oral 
candidiasis in which C. albicans plays a major role, such as DS. However, to broaden 
the knowledge about this nanocarrier, future studies assessing the MCZ release profiles, 
different treatment periods, as well as toxicity to human cells caused by IONPs-CS-
MCZ are needed.  
 
5. Conclusion 
The protocol used in the present study was successful for the assembly of the 
IONPs-CS-MCZ nanocarrier, revealing a spinel-structure (IONPs) enveloped by CS and 
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MCZ, with size smaller than 50 nm. The resulting nanocarrier showed superior 
antifungal effect to MCZ alone on planktonic cells of C. albicans (synergistic effect), 
while for C. glabrata cells an indifferent effect was observed. For biofilm assays, the 
nanocarrier containing 78 µg/mL MCZ led to higher reductions in some parameters of 
single- and dual-species biofilms (cultivable cells and metabolism) compared with free 
MCZ. Additionally, the nanocarrier advantage was more evident for C. albicans, 
suggesting a potential application for the treatment of oral candidiasis in which this 
fungus is the main responsible. The presence of an external magnetic field during 
biofilm treatment did not potentiate the nanocarrier’s antibiofilm effect. 
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Table and figure captions 
 
Table 1. Minimum inhibitory concentration (MIC) values of iron oxide magnetic 
nanoparticles (IONPs), chitosan (CS) and miconazole (MCZ), alone or in association, 
for the tested Candida strains 
 
Table 2. Mean values (standard deviation) of the protein content obtained from the 
extracellular matrix of single- and dual-species Candida biofilms after treatment with 
different compounds 
 
Figure 1. Transmission electron microscopy image (a), size distribution histogram (b), 
Fourier-transform infrared spectrum (c) and thermogravimetric analysis (d) for the iron 
oxide magnetic nanoparticles-chitosan-miconazole nanocarrier. Enlarged image in (a) 
represents the core of a chitosan-coated nanoparticle, and miconazole particles bound to 
chitosan. Red circle in (c) shows the region of characteristic bands of the presence of 
miconazole. 
 
Figure 2. Quantification of total biomass (mean absorbance values per cm2) for single- 
(a and b) and dual-species (c) biofilms of C. albicans ATCC 10231 and C. glabrata 
ATCC 90030 treated with 110 µg/mL iron oxide magnetic nanoparticles (IONPs), 110 
27 
 
µg/mL chitosan (CS), 78 µg/mL miconazole (MCZ) and MCZ-containing nanocarrier at 
31.2 (IONPs-CS-MCZ31.2) and 78 µg/mL (IONPs-CS-MCZ78), in the absence or 
presence of an external magnetic field. Negative control denotes non-treated biofilms 
(NC). Different uppercase and lowercase letters show significant differences among the 
treatments for biofilms treated in the absence and presence of an external magnetic 
field, respectively (2-way ANOVA and Holm-Sidak test, p < 0.05). 
 
Figure 3. Quantification of metabolic activity (mean absorbance values per cm2) for 
single- (a and b) and dual-species (c) biofilms of C. albicans ATCC 10231 and C. 
glabrata ATCC 90030 treated with 110 µg/mL iron oxide magnetic nanoparticles 
(IONPs), 110 µg/mL chitosan (CS), 78 µg/mL miconazole (MCZ) and MCZ-containing 
nanocarrier at 31.2 (IONPs-CS-MCZ31.2) and 78 µg/mL (IONPs-CS-MCZ78), in the 
absence or presence of an external magnetic field. Negative control denotes non-treated 
biofilms (NC). Different uppercase and lowercase letters show significant differences 
among the treatments for biofilms treated in the absence and presence of an external 
magnetic field, respectively (2-way ANOVA and Holm-Sidak test, p < 0.05). 
 
Figure 4. Quantification of cultivable cells (mean values of the logarithm of colony-
forming units per cm2) for single- (a and b) and dual-species (c and d) biofilms of C. 
albicans ATCC 10231 and C. glabrata ATCC 90030 treated with 110 µg/mL iron oxide 
magnetic nanoparticles (IONPs), 110 µg/mL chitosan (CS), 78 µg/mL miconazole 
(MCZ) and MCZ-containing nanocarrier at 31.2 (IONPs-CS-MCZ31.2) and 78 µg/mL 
(IONPs-CS-MCZ78), in the absence or presence of an external magnetic field. Negative 
control denotes non-treated biofilms (NC). Different uppercase and lowercase letters 
show significant differences among the treatments for biofilms treated in the absence 
and presence of an external magnetic field, respectively (2-way ANOVA and Holm-
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Sidak test, p < 0.05). Within each treatment, asterisk (*) indicates significant difference 
between biofilms treated in the absence and presence of an external magnetic field.  
 
Figure 5. Scanning electron microscopy imagens of dual-species biofilms of Candida 
albicans ATCC 10231 and C. glabrata ATCC 90030 treated with 110 µg/mL iron oxide 
magnetic nanoparticles (b), 110 µg/mL chitosan (c), 78 µg/mL miconazole (d) and 
miconazole-containing nanocarrier at 31.2 (e) and 78 µg/mL (f). Negative control 
denotes non-treated biofilm (a). Magnification: 2500x. Bars: 10 µm. Red arrows in 
images (c), (e) and (f) indicate particle clusters. 
 
Figure 6. Confocal laser scanning microscopy images of dual-species biofilms of 
Candida albicans ATCC 10231 and C. glabrata ATCC 90030 treated with 110 µg/mL 
iron oxide magnetic nanoparticles (b), 110 µg/mL chitosan (c), 78 µg/mL miconazole 
(d) and miconazole-containing nanocarrier at 31.2 (e) and 78 µg/mL (f). Negative 
control denotes non-treated biofilm (a). Magnification: 20x. Bars: 100 µm. 
Table 1. Minimum inhibitory concentration (MIC) values of iron oxide magnetic 
nanoparticles (IONPs), chitosan (CS) and miconazole (MCZ), alone or in association, for the 
tested Candida strains 
 





Species IONPs CS MCZ IONPs CS MCZ FICI Classification 
C. albicans 
ATCC 10231 
> 140 > 140 1.56 0.27 0.27 0.19 < 0.12 Synergism 
C. glabrata 
ATCC 90030 
> 140 > 140 
3.12– 
6.25 
2.18 2.18 1.56 < 0.53 Indifference 






Table 2. Mean values (standard deviation) of the protein content obtained from the extracellular matrix of single- 
and dual-species Candida biofilms after treatment with different compounds 
 
Proteins (mg/ml)  
Biofilms NC IONPs CS MCZ IONPs-CS-MCZ31.2 IONPs-CS-MCZ78 
 Presence of an external magnetic field 
C. albicans ATCC 10231 0.10 (0.05) 0.09 (0.00) 0.08 (0.01) 0.09 (0.02) 0.11 (0.03) 0.07 (0.02) 
C. glabrata ATCC 90030 0.04 (0.01) 0.07 (0.01) 0.08 (0.02) 0.04 (0.00) 0.06 (0.01) 0.06 (0.03) 
Dual-species biofilm 0.12 (0.09) 0.09 (0.04) 0.11 (0.04) 0.09 (0.05) 0.11 (0.02) 0.08 (0.00) 
 Absence of an external magnetic field 
C. albicans ATCC 10231 0.09 (0.02) 0.12 (0.08) 0.12 (0.06) 0.11 (0.05) 0.13 (0.05) 0.08 (0.01) 
C. glabrata ATCC 90030 0.06 (0.03) 0.10 (0.04) 0.09 (0.04) 0.05 (0.01) 0.06 (0.03) 0.05 (0.00) 
Dual-species biofilm 0.12 (0.08) 0.06 (0.03) 0.07 (0.02) 0.05 (0.01) 0.08 (0.04) 0.09 (0.06) 
Note: there were no statistically significant differences among the compounds, regardless of the presence of a magnetic field (2-way 
ANOVA;	 p<0.05). Negative control (NC); 110 µg/ml iron oxide magnetic nanoparticles (IONPs); 110 µg/ml chitosan (CS); 78 µg/ml 
miconazole (MCZ); MCZ-containing nanocarrier at 31.2 (IONPs-CS-MCZ31.2) and 78 µg/ml (IONPs-CS-MCZ78). 
Table 3. Mean values (standard deviation) of the carbohydrate content obtained from the extracellular matrix of 
single- and dual-species Candida biofilms after treatment with different compounds 
 
Carbohydrates (mg/ml)  
Biofilms NC IONPs CS MCZ IONPs-CS-MCZ31.2 IONPs-CS-MCZ78 
 Presence of an external magnetic field 
C. albicans ATCC 10231 0.74 (0.24) 0.57 (0.13) 0.56 (0.07) 0.75 (0.46) 0.74 (0.09) 0.63 (0.14) 
C. glabrata ATCC 90030 0.47 (0.40) 1.09 (0.66) 1.16 (0.78) 0.42 (0.35) 0.82 (0.24) 0.59 (0.59) 
Dual-species biofilm 0.77 (0.26) 0.65 (0.11) 0.62 (0.19) 0.74 (0.27) 0.74 (0.04) 0.65 (0.21) 
 Absence of an external magnetic field 
C. albicans ATCC 10231 0.68 (0.26) 0.48 (0.17) 0.62 (0.42) 0.33 (0.09) 0.53 (0.15) 0.38 (0.31) 
C. glabrata ATCC 90030 0.81 (0.76) 1.15 (0.97) 1.50 (0.72) 0.80 (0.48) 0.80 (0.20) 0.85 (0.40) 
Dual-species biofilm 0.55 (0.37) 0.83 (0.15) 0.52 (0.21) 0.67 (0.03) 0.84 (0.55) 0.48 (0.25) 
Note: there were no statistically significant differences among the compounds, regardless of the presence of a magnetic field (2-way 
ANOVA;	 p<0.05). Negative control (NC); 110 µg/ml iron oxide magnetic nanoparticles (IONPs); 110 µg/ml chitosan (CS); 78 µg/ml 
miconazole (MCZ); MCZ-containing nanocarrier at 31.2 (IONPs-CS-MCZ31.2) and 78 µg/ml (IONPs-CS-MCZ78). 
Table 4. Mean values (standard deviation) of the DNA content obtained from the extracellular matrix of single- and 
dual-species Candida biofilms after treatment with different compounds 
 
DNA (mg/ml)  
Biofilms NC IONPs CS MCZ IONPs-CS-MCZ31.2 IONPs-CS-MCZ78 
 Presence of an external magnetic field 
C. albicans ATCC 10231 0.03 (0.02) 0.03 (0.00) 0.02 (0.00) 0.04 (0.02) 0.04 (0.01) 0.04 (0.01) 
C. glabrata ATCC 90030 0.01 (0.01) 0.03 (0.01) 0.03 (0.00) 0.02 (0.00) 0.02 (0.00) 0.04 (0.02) 
Dual-species biofilm 0.04 (0.04) 0.03 (0.01) 0.03 (0.00) 0.04 (0.01) 0.04 (0.01) 0.04 (0.01) 
 Absence of an external magnetic field 
C. albicans ATCC 10231 0.03 (0.01) 0.03 (0.01) 0.02 (0.01) 0.03 (0.01) 0.04 (0.00) 0.03 (0.01) 
C. glabrata ATCC 90030 0.02 (0.01) 0.04 (0.03) 0.04 (0.02) 0.02 (0.00) 0.03 (0.02) 0.02 (0.00) 
Dual-species biofilm 0.03 (0.01) 0.03 (0.01) 0.03 (0.00) 0.03 (0.00) 0.04 (0.01) 0.03 (0.01) 
Note: there were no statistically significant differences among the compounds, regardless of the presence of a magnetic field (2-way 
ANOVA;	 p<0.05). Negative control (NC); 110 µg/ml iron oxide magnetic nanoparticles (IONPs); 110 µg/ml chitosan (CS); 78 µg/ml 
miconazole (MCZ); MCZ-containing nanocarrier at 31.2 (IONPs-CS-MCZ31.2) and 78 µg/ml (IONPs-CS-MCZ78). 






